This product was designed to determine the genotype by amplifying and analyzing the specific base sequence of 17 mutations of CYP2D6 and confirming the presence or absence of CYP2D6 mutations and specific nucleic acid sequences. After amplifying the gene with CYP2D6 specific primer, SNaPshot reaction is performed using specific primers to detect specific SNPs of CYP2D6, 100C>T, 1023C>T, 1611T>A, 1707delT, 1758G>A, 1846G>A, 1887insTA, 2549delA, 2573_2574insC, 2615_2617delAAG, 2850C>T, 2988G>A, 3183G>A, 3877G>A, 4125_4133dup GTGCCCAT, deletion, and duplication. SNPs in the products obtained through SNaPshot reaction can be identified as peaks, and the mutations of each peak can be identified by the color of each peak. This product uses the testing principle of single-base extension (SBE), and is a qualitative analysis in vitro diagnostic medical device that can identify mutations in the form of peaks by combining amplified CYP2D6 products, fluorescent substances including ddNTPs, and primers manufactured just before mutation. The presence or absence of CYP2D6 mutations is determined based on the analysis results of the Wild Type DNA included in the product. Samples with CYP2D6 mutations show peaks with distinct color and height differences compared to Wild Type DNA, allowing for accurate detection of CYP2D6 mutations. Confirmation of CYP2D6 mutations can help in selecting drugs metabolized by CYP2D6, adjusting the dosage, etc.